Literature DB >> 10084046

A population-based study on uveitis in juvenile rheumatoid arthritis.

K Kotaniemi1, O Kaipiainen-Seppänen, A Savolainen, A Karma.   

Abstract

OBJECTIVE: To obtain information on the occurrence and characteristics of uveitis in a population-based survey of patients with juvenile rheumatoid arthritis (JRA).
METHODS: The subjects in this study were entitled, under the nationwide sickness insurance scheme, to receive specially reimbursed medication for JRA in 5 of the 21 central hospital districts in Finland (population base about 270,000 children < 16 years of age) in 1980, 1985 and 1990.
RESULTS: A total of 114 incident cases (34 boys and 80 girls) satisfied the criteria for JRA. Uveitis was diagnosed in 18 of these patients (16%). The mean age of uveitis patients at the diagnosis of JRA was 6.8 years (median 5.4 years) and the mean interval from the diagnosis of JRA to the detection of uveitis was 2.9 years. Silent (asymptomatic) anterior uveitis was found in 4 boys and 11 girls and acute anterior uveitis in 2 boys. One girl had marginal corneal ulceration with mild anterior uveitis. Uveitis was chronic (> 6 months) in 9 cases. Uveal inflammation was most severe in the 3 children whose uveitis was detected at the time of the diagnosis of JRA.
CONCLUSION: The study provides population-based information on the occurrence and characteristics of uveitis associated with JRA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084046

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

Review 1.  Uveitis in juvenile idiopathic arthritis.

Authors:  Arnd Heiligenhaus; Kirsten Minden; Dirk Föll; Uwe Pleyer
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

2.  [Vision-threatening complications in childhood uveitis].

Authors:  A Mingels; T Hudde; C Heinz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

Review 3.  Prevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitis.

Authors:  Sheila Angeles-Han; Steven Yeh
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

4.  Uveitis in children and adolescents.

Authors:  D BenEzra; E Cohen; G Maftzir
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

5.  Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature.

Authors:  Petros E Carvounis; David C Herman; Stephen Cha; James P Burke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-14       Impact factor: 3.117

6.  Ocular manifestations of juvenile rheumatoid arthritis in Olmsted County, Minnesota: a population-based study.

Authors:  Petros E Carvounis; David C Herman; Stephen S Cha; James P Burke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-17       Impact factor: 3.117

7.  Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis.

Authors:  Sheila T Angeles-Han; Steven Yeh; Larry B Vogler
Journal:  Int J Clin Rheumtol       Date:  2013-02-01

8.  Impact of Juvenile Idiopathic Arthritis Associated Uveitis in Early Adulthood.

Authors:  Anne-Mieke J W Haasnoot; Lenneke A Vernie; Aniki Rothova; Patricia V D Doe; Leonoor I Los; Nicoline E Schalij-Delfos; Joke H de Boer
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

9.  Role of Chronic Inflammation in Myopia Progression: Clinical Evidence and Experimental Validation.

Authors:  Hui-Ju Lin; Chang-Ching Wei; Ching-Yao Chang; Ter-Hsin Chen; Yu-An Hsu; Yi-Ching Hsieh; Hsuan-Ju Chen; Lei Wan
Journal:  EBioMedicine       Date:  2016-07-19       Impact factor: 8.143

10.  Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.

Authors:  Christoph Tappeiner; Sandra Schenck; Martina Niewerth; Arnd Heiligenhaus; Kirsten Minden; Jens Klotsche
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.